CARLSBAD, Calif., March 10, 2016 (GLOBE NEWSWIRE) -- Signal Genetics, Inc. (NASDAQ:SGNL) (Signal or the Company), a commercial stage, molecular genetics diagnostic company focused on providing innovative diagnostic services that help physicians make better-informed decisions concerning the care of their patients suffering from cancer, today announced that the Company will report financial results for the fourth quarter and fiscal year ended December 31, 2015 on Wednesday, March 16, 2016, after the close of the market. Following the announcement, a live conference call and webcast will be held at 4:30 p.m. (ET) to provide investors with an annual corporate update.
The conference call can be accessed by dialing 1-877-407-0784 for domestic callers, and 1-201-689-8560 for international callers. The conference ID number is 13632678. In addition to the call, a live webcast of the event will be available on the investor relations page of the Company's website at www.signalgenetics.com.
Following the call, the event will remain archived on the Signal Genetics website for 30 days. In addition to the archive, a recording of the call will be available until March 30, 2016. The recording can be accessed by dialing 1-877-870-5176 for domestic callers, and 1-858-384-5517 for international callers. The conference ID number for the recording is 13632678.
About Signal Genetics, Inc.
Signal Genetics, Inc., headquartered in Carlsbad, California, is a commercial stage, molecular diagnostic company focused on providing innovative diagnostic services that help physicians make better-informed decisions concerning the care of their patients suffering from cancer. Signal's mission is to develop, validate and deliver innovative diagnostic services that enable better patient-care decisions. Signal was founded in January 2010 and became the exclusive licensee in its licensed field to the renowned research on multiple myeloma performed at the University of Arkansas for Medical Sciences, in April 2010. The company is dedicated to making its extensively validated diagnostic services available to all patients who need them.
Safe Harbor Statement
All statements included in this press release that are not historical are forward-looking statements. These forward-looking statements can generally be identified as such because the context of the statement will include words such as “may,” “will,” “intend,” “plans,” “believes,” “anticipates,” “expects,” “estimates,” “predicts,” “potential,” “continue,” “opportunity,” “goals,” or “should,” the negative of these words or words of similar import. Similarly, statements that describe our future plans, strategies, intentions, expectations, objectives, goals, or prospects are also forward-looking statements. These forward-looking statements are or will be, as applicable, based largely on our expectations and projections about future events and future trends affecting our business, and so are or will be, as applicable, subject to risks and uncertainties including, but not limited to, the risk factors discussed in our periodic reports filed with the Securities and Exchange Commission, that could cause actual results to differ materially from those anticipated in the forward-looking statements. We caution investors that there can be no assurance that actual results or business conditions will not differ materially from those projected or suggested in such forward-looking statements. The forward-looking statements included in this press release speak only as of the date of this press release. Our views and the events, conditions and circumstances on which these future forward-looking statements are based, may change. We do not assume any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or developments, or otherwise, except as may be required by the securities laws, and we caution you not to rely on them unduly. All forward-looking statements are qualified in their entirety by this cautionary statement.
INVESTOR CONTACT: The Ruth Group David Burke Tel: 646-536-7009 email@example.com
Source:Signal Genetics, Inc.